RBC Capital on Karuna Therapeutics Inc. (KRTX) via Cerevel (CERE) Data: 'KarXT sets a high bar for future muscarinic agents'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $286.00 price target on Karuna Therapeutics Inc. (NASDAQ: KRTX)Cerevel Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
